- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Sexual abuse.
Displaying page 1 of 2.
| EudraCT Number: 2014-000647-32 | Sponsor Protocol Number: PRIOTAB | Start Date*: 2014-10-22 |
| Sponsor Name:Karolinska University Hospital | ||
| Full Title: Investigation of the efficacy of degarelix as an acute treatment for patients with pedophilic disorder to reduce the risk for sexual child molestation: a prospective, randomized, double blind, and ... | ||
| Medical condition: Pedophilia acccording to DSM-5 (F65.4) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002369-14 | Sponsor Protocol Number: CHUB-Psy-PAThforsAUD | Start Date*: 2023-07-20 | |||||||||||
| Sponsor Name:CHU Brugmann | |||||||||||||
| Full Title: Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms. | |||||||||||||
| Medical condition: Severe Alcohol Use Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004823-66 | Sponsor Protocol Number: ELTCAN1 | Start Date*: 2019-04-17 | |||||||||||
| Sponsor Name:Radboudumc | |||||||||||||
| Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction | |||||||||||||
| Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002097-38 | Sponsor Protocol Number: ABR62020 | Start Date*: 2018-06-05 |
| Sponsor Name:University Medical Centre Utrecht | ||
| Full Title: SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial | ||
| Medical condition: Depressive episode in people with childhood trauma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000069-57 | Sponsor Protocol Number: P15-01 | Start Date*: 2017-07-21 | |||||||||||
| Sponsor Name:BIOPROJET PHARMA | |||||||||||||
| Full Title: A Multisite Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment | |||||||||||||
| Medical condition: Male or female with moderate or severe DSM-5 alcohol use disorder (based on the alcohol use disorders section of MINI) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002161-56 | Sponsor Protocol Number: NeM-CSM-FT-01 | Start Date*: 2017-04-13 |
| Sponsor Name:Mateusz Gola | ||
| Full Title: Towards the understanding of neuronal mechanisms of compulsive sexual behaviors - pharmacotherapy | ||
| Medical condition: compulsive sexual behavior (hypersexual disorder) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: PL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
| Sponsor Name:Radboudumc | |||||||||||||
| Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
| Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003257-42 | Sponsor Protocol Number: ACH-CYT-02 | Start Date*: 2017-10-03 |
| Sponsor Name:Achieve Life Sciences Inc | ||
| Full Title: Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers | ||
| Medical condition: Smoking cessation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000536-95 | Sponsor Protocol Number: SLx-4090-07-03 | Start Date*: 2007-05-08 | |||||||||||
| Sponsor Name:Surface Logix | |||||||||||||
| Full Title: A randomised, double-blind, placebo controlled study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics profile of SLx-4090 over 14 days dosing in subjects with high trigly... | |||||||||||||
| Medical condition: Dyslipidemia/hypertriglyceridemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001385-16 | Sponsor Protocol Number: BACTstudy | Start Date*: 2019-11-22 |
| Sponsor Name:Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT) | ||
| Full Title: Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial | ||
| Medical condition: Frequent and chronic tension-type headache | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004842-40 | Sponsor Protocol Number: K020-218 | Start Date*: 2019-08-21 | |||||||||||
| Sponsor Name:Kaleido Biosciences | |||||||||||||
| Full Title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | |||||||||||||
| Medical condition: Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000685-15 | Sponsor Protocol Number: AXA1125-101 | Start Date*: 2021-10-18 | |||||||||||
| Sponsor Name:Axcella Health, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi... | |||||||||||||
| Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000320-40 | Sponsor Protocol Number: SLx-2101-07-05 | Start Date*: 2007-06-14 | |||||||||||
| Sponsor Name:Surface Logix, Inc. | |||||||||||||
| Full Title: A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5,... | |||||||||||||
| Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005969-13 | Sponsor Protocol Number: AXA1665-101 | Start Date*: 2021-08-11 | ||||||||||||||||
| Sponsor Name:Axcella Health, Inc. | ||||||||||||||||||
| Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EM... | ||||||||||||||||||
| Medical condition: Overt Hepatic Encephalopathy in Subjects with Liver Cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004971-30 | Sponsor Protocol Number: FLUGEN-H3N2-V002 | Start Date*: 2018-04-27 | |||||||||||
| Sponsor Name:FluGen, Inc | |||||||||||||
| Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranas... | |||||||||||||
| Medical condition: Prophylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002920-14 | Sponsor Protocol Number: VX-950-TiDP24-C209 | Start Date*: 2007-11-14 | |||||||||||
| Sponsor Name:Tibotec BVBA | |||||||||||||
| Full Title: A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection | |||||||||||||
| Medical condition: Hepatitis C infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-002088-18 | Sponsor Protocol Number: H3A106104 | Start Date*: 2006-10-12 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy. | |||||||||||||
| Medical condition: Narcolepsy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-003087-43 | Sponsor Protocol Number: SAFER | Start Date*: 2021-01-12 | |||||||||||
| Sponsor Name:Synektik Spółka Akcyjna | |||||||||||||
| Full Title: A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emis... | |||||||||||||
| Medical condition: phase II: suspected coronary artery disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-001044-44 | Sponsor Protocol Number: VX-950-TiDP24-C208 | Start Date*: 2007-08-01 | |||||||||||
| Sponsor Name:Tibotec BVBA | |||||||||||||
| Full Title: A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... | |||||||||||||
| Medical condition: Hepatitis C infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003629-86 | Sponsor Protocol Number: ING114915 | Start Date*: 2012-01-27 | |||||||||||
| Sponsor Name:Viiv Healthcare | |||||||||||||
| Full Title: A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini... | |||||||||||||
| Medical condition: HIV-1 infection in ART-naïve subjects. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.